Cellular uptake mechanism and therapeutic utility of a novel peptide in targeted-delivery of proteins into neuronal cells

Pharmaceutical Research

Volumn 30, Issue 8, 2013, Pages 2108-2117

  Fu, Ailing ^a   Zhao, Zizhen ^b   Gao, Feiyan ^a   Zhang, Miaomiao ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Brain targeting delivery; Internalization mechanism; Parkinson's disease; RDP

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMPHETAMINE; ANTIPARKINSON AGENT; APOMORPHINE; CLATHRIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PEPTIDE; RECOMBINANT DNA;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TRANSPORT;

AMINO ACID SEQUENCE; ANIMALS; BRAIN; CELL LINE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GAMMA-AMINOBUTYRIC ACID; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEURONS; PARKINSONIAN DISORDERS; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 84879793886     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1068-6     Document Type: Article

References (44)

1. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23.
2. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol. 2004;19(2):535-64.
3. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target. 2010;18(3):157-67.
4. Trabulo S, Cardoso AL, Mano M, de Lima MCP. Cell-penetrating Peptides - mechanisms of cellular uptake and generation of delivery systems. Pharmceuticals. 2010;3:961-93.
5. Tan ML, Choong PF, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptide. 2009;31(1):184-93.
6. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol. 2009;157(2):195-206.
7. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433):1569-72.
8. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57(4):637-51.
9. Martín I, Teixidó M, Giralt E. Building cell selectivity into CPP-mediated strategies. Pharmceuticals. 2010;3:1456-90.
10. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003;278(1):585-90.
11. Fu A, Wang Y, Zhan L, Zhou R. Targeted delivery of proteins into the central nervous system mediated by Rabies Virus glycoprotein-derived peptide. Pharm Res. 2012;29(6):1562-9.
12. Tuffereau C, Benejean J, Alfonso AR, Flamand A, Fishman AC. Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of lepidopteran cells. J Virol. 1998;72:1085-91.
13. Fu AL, Fan L, Li S, Manji S. Role of extracellular signal-regulated kinase signal transduction pathway in anxiety. J Psychiatr Res. 2008;43(1):55-63.
14. Fu AL, Wu SP, Dong ZH, Sun MJ. A novel therapeutic approach to depression via supplement with tyrosine hydroxylase. Biochem Bioph Res Co. 2006;351(1):140-5.
15. Fu AL, Zhou CY, Chen X. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease. Neuropharmacology. 2010;58(4-5):722-9.
16. Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol. 2008;210(1):182-93.
17. Fu AL, Zhou QH, Hui EK, Lu JZ, Boado RJ, Pardridag WM. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res. 2010;1352:208-13.
18. Zhang Y, Pardridge WM. Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. Pharm Res. 2009;26(5):1059-63.
19. Kim K, Malik AB. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L247-59.
20. Rydström A, Deshayes S, Konate K, Crombez L, Padari K, Boukhaddaoui H, et al. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS One. 2011;6(10):e25924.
21. Zhang X, Jin Y, Plummer MR, Pooyan S, Gunaseelan S, Sinko PJ. Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso Tat cell penetrating peptide. Mol Pharm. 2009;6(3):836-48.
22. Mussbach F, Franke M, Zoch A, Schaefer B, Reissmann S. Transduction of peptides and proteins into live cells by cell penetrating peptides. J Cell Biochem. 2011;112(12):3824-33.
23. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol. 1996;12:575-625.
24. Tang Q, Orciari LA, Rupprechti CE, Zhao XQ, Li ZG, Yang WS. Sequencing and position analysis of the glycoprotein gene of four Chinese rabies viruses. Virol Sin. 2000;15(1):22-33.
25. Young AB, Chu D. Distribution of GABA, and GABA, receptors in mammalian brain: potential targets for drug development. Drug Develop Res. 1990;21(3):161-7.
26. Guo L, Ren J, Jiang X. Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol. 2012;13(12):2310-8.
27. Ambikanandan M, Ganesh S, Aliasgar S. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci. 2003;6(2):252-73.
28. Keller A, Mussbach F, Breitling R, Hemmerich P, Schaefer B, Lorkowski S, et al. Relationships between cargo, cell penetrating peptides and cell type for uptake of non-covalent complexes into live cells. Pharmaceuticals. 2013;6:184-203.
29. Ma D, Qi X. Comparison of mechanisms and cellular uptake of cell-penetrating peptide on different cell lines. Acta Pharmacol Sin. 2010;45(9):1165-9.
30. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39-43.
31. Hwang do W, Son S, Jang J, Youn H, Lee S, Lee D, et al. Brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials. 2011;32(21):4968-75.
32. Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials. 2009;30(25):4195-202.
33. Tuffereau C, Leblois H, Bénéjean J, Coulon P, Lafay F, Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virol. 1989;172(1):206-12.
34. Benmansour A, Leblois H, Coulon C, Tuffereau C, Gaudin Y, Flamand A, et al. Antigenicity of rabies virus glycoprotein. J Virol. 1991;65:4198-203.
35. Whiting PJ. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today. 2003;8(10):445-50.
36. Smith KR, Muir J, Rao Y, Browarski M, Gruenig MC, Sheehan DF, et al. Stabilization of GABA(A) receptors at endocytic zones is mediated by an AP2 binding motif within the GABA(A) receptor β3 subunit. J Neurosci. 2012;32(7):2485-98.
37. Ulens C, Hogg RC, Celie PH, Bertrand D, Tsetlin V, Smit AB, et al. Structural determinants of selective alpha-conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. Proc Natl Acad Sci USA. 2006;103(10):3615-20.
38. Yasuda T, Mochizuki H. Use of growth factors for the treatment of Parkinson's disease. Expert Rev Neurother. 2010;10(6):915-24.
39. Mickiewicz AL, Kordower JH. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011;10(6):703-11.
40. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett. 1994;182(1):107-11.
41. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459-66.
42. Kilic U, Kilic E, Dietz GP, Bähr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke. 2003;34(5):1304-10.
43. Dietz GP, Valbuena PC, Dietz B, Meuer K, Müeller P, Weishaupt JH, et al. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 2006;1082(1):61-6.
44. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci. 2006;27(4):311-9.